Click here to go to the previous page
Implementing Adaptive Clinical Trials: A Practical Perspective
Program Code:
248
Date:
Tuesday, June 26, 2012
Time:
1:30 PM to 3:00 PM
EST
CHAIR
:
Bill Byrom,
Perceptive Informatics, United Kingdom
Bill joined the Pharmaceutical industry in 1991 after completing a PhD in disease control simulation at Strathclyde University, and has worked in a number of roles within Statistics, Clinical Development and International Marketing. At Perceptive, Bill is Senior Director of Product Strategy.
|
PRESENTER
(S):
Graham Nicholls, Almac Clinical Technologies LLC, United Kingdom
Bill Byrom,
Perceptive Informatics, United Kingdom
Bill joined the Pharmaceutical industry in 1991 after completing a PhD in disease control simulation at Strathclyde University, and has worked in a number of roles within Statistics, Clinical Development and International Marketing. At Perceptive, Bill is Senior Director of Product Strategy.
|
Dr Martin Kimber originally trained as a particle physicist and joined Tessella in 2001. Since 2006 he has led Tessella's clinical trial execution projects, focused on dose-ranging/dose-escalation Bayesian response-adaptive designs. He is a member of the DIA ADSWG Adaptive Programs research group.
|
Description
During the past decade we have seen increasing interest in adaptive trial designs, and with the release of regulatory agency guidelines a cautious encouragement and acceptance of the methodology now prevails. Nevertheless, while the promise of these designs is acknowledged, the operational challenges in their implementation are less well understood. Through three presentations, this session explores different aspects of practical implementation of adaptive clinical trials in clinical development programs. We will focus on practical implementation learning using case study illustrations where possible.
Learning Objectives:
Discuss how clinical trials technologies enable the effective implementation of adaptive trials
Describe and appraise different supply planning, manufacture, packaging, and labeling strategies for adaptive trials: Describe the operation of the data monitoring committee and how to manage interim analyses and study stopping effectively.